All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Early detection of chronic HCV infection and eventually treatment and lifestyle/ behavioral changes cannot only prevent sequelae such as cirrhosis, end-stage liver disease or HCC, but also interrupts infection transmission \[[@pone.0168649.ref001]\].

HCV is arguably the major public health challenge facing Egypt today. The virus shows evidence of continuous transmission in health care settings as well as within households \[[@pone.0168649.ref002]\]. Due to the absence of vaccines and drugs for post-exposure prophylaxis, precautionary measures preventing future spread is the cornerstone for prevention \[[@pone.0168649.ref003]\].

Because of the asymptomatic nature of HCV infection before diseases progression, many HCV infected individuals are not aware of their condition and therefore do not seek help or perceive a need to screen for HCV infection. As a result, a potentially large number of infected individuals remain unidentified or are identified late \[[@pone.0168649.ref003]\]. A major barrier to seeking HCV treatment is unawareness of HCV seropositivity \[[@pone.0168649.ref004]\].

People identified to be HCV infected benefit from counseling, risky behavior modification, HAV or HBV vaccinations, alcohol cessation and other interventions including the recently released effective antiviral treatment \[[@pone.0168649.ref005]\].

To control the epidemic in Egypt, extensive efforts should be directed towards identifying apparently healthy individuals with HCV infection. Risk calculation approaches have been widely applied in public health actions and clinical care and have even been accepted as preliminary diagnosis for some diseases \[[@pone.0168649.ref006]\].

The United States Preventive Services Task Force (USPSTF) concluded in 2004 that screening high-risk population would be more efficient strategy than screening average--risk population \[[@pone.0168649.ref007]\]. With increasing recognition of the clinical and public health benefit of early detection, a simple self-administered tool may provide means to identify infected individuals \[[@pone.0168649.ref008]--[@pone.0168649.ref010]\].

Few studies have evaluated screening tools for estimating risk for HCV infection to support efficient screening of the hidden population of HCV--infected individuals \[[@pone.0168649.ref011], [@pone.0168649.ref012]\]. Further research is needed to understand the effects of different strategies on clinical outcomes and to customize the tool to the target population. Accordingly, we -in a previous study \[[@pone.0168649.ref013]\]- developed a short version risk assessment tool for HCV infection screening in Egypt (EGCRISC). The present large scale cross-sectional study is aiming to validate and modify -if needed- the EGCRISC tool to be more effective in identifying those at increased risk of HCV infection in the Egyptian setting, a step in a road to apply this tool in the primary care settings and as an internet-based screening program.

Methods {#sec002}
=======

Development of the prediction model {#sec003}
-----------------------------------

The risk assessment tool abstracted from the first phase \[[@pone.0168649.ref013]\] was developed through a multivariate model of independent predictors of HCV seropositivity, that included the significant factors detected in the bivariate analysis among two age strata (\<45 and \>45 years) for each gender. Variables were ranked by their magnitude of risk \[(Odds Ratio (OR)\], with an overall score represented by the simple arithmetic sum of the nearest integral values. "[Table 1](#pone.0168649.t001){ref-type="table"}" summarizes the 17 overlapping predictors, ranging from 8 to 13 in each of the four stratified groups. The OR for each factor assigned its score, giving a different total score for each stratum. The cut-off value for each group was estimated using ROC curve analysis, based on Youden index criterion, to specify the discriminating point of the highest sensitivity and specificity.

10.1371/journal.pone.0168649.t001

###### Summary of EGCRISC strata, factors, scores and cut-off points.
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  Risk Factor                         Score                      
  ----------------------------------- -------- -------- -------- --------
  Blood/blood products transfusion    **9**    **8**    **4**    **2**
  Rural Residence                     **8**    **15**   **18**   **7**
  Fatigue                             **7**    **2**    **3**    **2**
  History of jaundice                 **6**    **3**    **4**    **1**
  History of PAT                      **2**    **3**    **9**    **6**
  Incarceration                       **2**    **4**    **-**    **-**
  Unsafe rout of sex                  **2**    **-**    **-**    **-**
  Contact with jaundice patient       **2**    **-**    **-**    **-**
  Use of barber or beautician tools   **2**    **-**    **-**    **3**
  Substance abuse                     **2**    **3**    **-**    **-**
  Living abroad                       **2**    **2**    **-**    **-**
  Hospitalization                     **2**    **-**    **3**    **-**
  Needle prick                        **2**    **2**    **-**    **2**
  History of invasive procedures      **-**    **2**    **3**    **-**
  Menses during intercourse           **-**    **-**    **4**    **-**
  Blood sample                        **-**    **-**    **2**    **-**
  Labour and delivery at home         **-**    **-**    **-**    **2**
  Total                               **47**   **44**   **50**   **25**
  Cut-off value                       **11**   **8**    **11**   **7**

Sample size {#sec004}
-----------

A sample of 4100 persons are required to estimate expected agreement with phase I scoring for predicting HCV infection status to be on average 70% with a tolerated error margin of 2%, confidence level of 95% and design effect = 2.

Sampling technique and methods of selection {#sec005}
-------------------------------------------

During this validation phase, the tool was applied to a stratified cluster sampling from urban and rural areas using a proportional allocation technique in governorates representing upper and lower Egypt considering a rural to urban ratio of 1.3:1 according to the latest national estimates \[[@pone.0168649.ref014]\]. In each governorate, a number of districts were selected at random where participants older than 15 years were voluntarily recruited.

Laboratory investigations {#sec006}
-------------------------

According to the pre-specified cutoff points for males and females in both age groups (above and below 45 years), the cross sectional sample individuals were classified to potentially HCV infected and potentially non-HCV infected. The actual HCV status was determined using commercial 3^rd^ generation ELISA kits (DIALAB^®^, Austria). Confirmation of ELISA results was done using a kit from a different supplier (DiaSorin Murex^®^, version 4.0, Italy). Quantitative real time PCR was done for ELISA positive subjects to test for HCV-RNA. A cross validation between the predicted status by EGCRISC score and the actual status was done by calculating classification accuracy rate and the degree of agreement between both tests. A new cutoff points for EGCRISC score system was derived using c statistic of ROC curve to estimate the distance between the extracted point and the previously determined one by the case control phase as a crude measure of validity for the old score.

Zones {#sec007}
-----

Being at risk of having HCV based on a total score of the risk factors was categorized into zones; low risk (green zone), moderate risk (yellow zone) and high risk (red zone) using cluster analysis depending on the very large sample size and including all scored factors for discriminating cases into 3 groups using K-Means clustering technique, then and after identifying the extracted groups (clusters) of cases, the upper and lower limit for the overall score was identified as borders for each area which showed good concordance with the actual binary classification of persons.

Ethical statement {#sec008}
-----------------

The present study was approved by the ethics committee and institutional review board of the High Institute of Public Health, Alexandria University (Egypt). The research conformed to the ethical guidelines of the Declaration of Helsinki (2013) and the International Conference on Harmonization Guidelines for Good Clinical Practice. An informed written consent was signed by all participants invited after elaborating on the study aim and concerns. Data sheets were coded to ensure anonymity and confidentiality of participants' data.

Results {#sec009}
=======

The study comprised a total of 4579 participants (55.7% males, 44.3% females) recruited from different urban and rural areas in Egypt "[Table 2](#pone.0168649.t002){ref-type="table"}". The mean age was 41.1±12.2. Other sociodemographic characteristics and a list of the studied HCV risk factors are detailed in "[Table 3](#pone.0168649.t003){ref-type="table"}". Stratified analysis of HCV risk factors by age and gender is displayed in ([S1 Table](#pone.0168649.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0168649.t002

###### The studied cases according to the their demographics and HCV status in the study settings.

![](pone.0168649.t002){#pone.0168649.t002g}

  Item                 Setting                                                                                                                                                                                                                                                                                                     
  -------------------- ------------- -------------------------------------------------------------------------------------- ------------ -------------------------------------------------------------------------------------- ------ ------------------------------------------------------------------------------------- ----- -------------------------------------------------------------------------------------
  **Gender**                                                                                                                                                                                                                                                                                                                       
      Female           730           52.0                                                                                   31           30.1                                                                                   679    33.3                                                                                  590   56.9
      Male             673           48.0                                                                                   72           69.9                                                                                   1357   66.7                                                                                  447   43.1
  **Age**                                                                                                                                                                                                                                                                                                                          
      \<45             707           50.4                                                                                   53           51.5                                                                                   1329   65.3                                                                                  597   57.6
      45+              696           49.6                                                                                   50           48.5                                                                                   707    34.7                                                                                  440   42.4
  **Mean ± SD**        42.5 ± 15.4   42.7 ± 8.6                                                                             39.8± 11.2   41.3 ± 13.9                                                                                                                                                                               
  **Anti-HCV ELISA**                                                                                                                                                                                                                                                                                                               
      Negative         1205          85.9                                                                                   98           95.1                                                                                   1932   94.9                                                                                  950   91.6
      Positive         198           14.1                                                                                   5            4.9                                                                                    104    5.1                                                                                   87    8.4
  **PCR**                                                                                                                                                                                                                                                                                                                          
      Negative         1231          87.7                                                                                   98           95.1                                                                                   1955   96.0                                                                                  965   93.1
      Positive         172           86.9[\^](#t002fn001){ref-type="table-fn"}(12.3)[\*](#t002fn002){ref-type="table-fn"}   5            100.0[\^](#t002fn001){ref-type="table-fn"}(4.9)[\*](#t002fn002){ref-type="table-fn"}   81     77.9[\^](#t002fn001){ref-type="table-fn"}(4.0)[\*](#t002fn002){ref-type="table-fn"}   72    82.8[\^](#t002fn001){ref-type="table-fn"}(6.9)[\*](#t002fn002){ref-type="table-fn"}

\^percentage from the ELISA positive subjects.

\*percentage from the total.

10.1371/journal.pone.0168649.t003

###### Sociodemographics and HCV risk factors including those of EGCRISC.

![](pone.0168649.t003){#pone.0168649.t003g}

  Factor                                     Anti-HCV ELISA             OR (95% CI)                                      
  ------------------------------------------ -------------------------- ------------- ------ ------ -------------------- -----------------------
  **Residence**                              Urban                      1834          95.5   87     4.5                  **2.8 (2.2--3.5)**
  Rural                                      2351                       88.4          307    11.6                        
  **Education**                              Illiterate /read & write   1440          84.7   261    15.3                 **4.4 (2.9--6.7)**
  Basic                                      699                        95.1          36     4.9    1.3 (0.74--2.1)      
  Secondary                                  1437                       95.2          72     4.8    1.2 (0.76--1.9)      
  University / more                          609                        96.1          25     3.9    ®                    
                                             Single                     465           98.9   5      1.1                  ®
  **Marital status**                         Married                    3394          91     336    9                    **9.2 (3.8--22.4)**
                                             Divorced/widow             326           86     53     14                   **15.1 (5.9--38.2)**
                                             Not working                1519          91.1   148    8.9                  ref
  **Job nature**                             Low risk                   2102          92.4   174    7.6                  0.85 (0.67--1.1)
                                             High risk                  564           88.7   72     11.3                 1.3 (0.97--1.8)
  **Working abroad**                         No                         3615          91.9   318    8.1                  ®
  Yes                                        570                        88.2          76     11.8   **1.5 (1.2--1.9)**   
  **Tattooing**                              No                         3878          91.3   370    8.7                  0.82 (0.53--1.3)
  Yes                                        307                        92.7          24     7.3                         
  **Ear / body piercing**                    No                         2308          90.8   234    9.2                  0.84 (0.68--1.1)
  Yes                                        1877                       92.1          160    7.9                         
  **Shared instruments**                     No                         904           90     101    10                   0.80 (0.63--1.1)
  Yes                                        3281                       91.8          293    8.2                         
  **Use barber tools**                       No                         1026          88.4   134    11.6                 **0.63 (0.51--0.78)**
  Yes                                        3159                       92.4          260    7.6                         
  **Pierced with blood contaminated tool**   No                         3851          91.5   357    8.5                  1.2 (0.83--1.7)
  Yes                                        334                        90            37     10                          
  **Bitten by animal**                       No                         3386          91.4   317    8.6                  1.0 (0.79--1.3)
  Yes                                        799                        91.2          77     8.8                         
  **Exposed to blood**                       No                         3305          91.6   305    8.4                  1.1 (0.86--1.4)
  Yes                                        880                        90.8          89     9.2                         
  **Blood / blood products transfusion**     No                         3858          92.2   326    7.8                  **2.5 (1.9--3.2)**
  Yes                                        327                        82.8          68     17.2                        
  **History of jaundice**                    No                         3814          91.5   353    8.5                  **1.2 (0.99--1.7)**
  Yes                                        371                        90            41     10                          
  **Family member with hepatic disease**     No                         3503          91.5   326    8.5                  1.1 (0.82--1.4)
  Yes                                        682                        90.9          68     9.1                         
                                             No                         591           93.2   43     6.8                  ®
  **Blood sampling**                         \<10 years                 2757          92.2   234    7.8                  1.2 (0.83--1.6)
                                             \>10 years                 837           87.7   117    12.3                 1.9 (0.89--2.7)
  **Previous hospitalization**               No                         1914          91.2   185    8.8                  0.95 (0.77--1.2)
  Yes                                        2271                       91.6          209    8.4                         
  **Bilharziasis**                           No                         2886          96.1   116    3.9                  **5.3 (4.2--6.7)**
  Yes                                        1299                       82.4          278    17.6                        
  **Genital ulcers**                         No                         3236          92     281    8                    1.4 (1.0--1.7)
  Yes                                        949                        89.4          113    10.6                        
  **Circumcision**                           No                         1061          96.6   37     3.4                  **3.3 (2.3--4.6)**
  Yes                                        3124                       89.7          357    10.3                        
  **Tarter injections for Bilharziasis**     No                         3634          95.4   177    4.6                  **8.1 (6.5--10.1)**
  Yes                                        551                        71.7          217    28.3                        
  **History of oral ulcers**                 No                         2749          92     239    8                    1.2 (1.0--1.5)
  Yes                                        1436                       90.3          155    9.7                         
  **Invasive procedure**                     No                         3146          92.3   261    7.7                  **1.5 (1.2--1.9)**
  Yes                                        1039                       88.7          133    11.3                        
  **Acupuncture**                            No                         4075          91.3   389    8.7                  0.47 (0.19--1.2)
  Yes                                        110                        95.7          5      4.3                         
  **History of incarceration**               No                         4098          91.4   385    8.6                  1.1 (0.55--2.2)
  Yes                                        87                         90.6          9      9.4                         
  **Opioid injection**                       No                         4183          91.4   393    8.6                  5.3 (0.48--58.2)
  Yes                                        2                          66.7          1      33.3                        
  **Drink alcohol**                          No                         3998          91.6   368    8.4                  1.5 (0.98--2.3)
  Yes                                        187                        87.8          26     12.2                        
  **Waterpipe smoking (Shisha)**             No                         3423          91.7   311    8.3                  1.1 (0.93--1.5)
  Yes                                        762                        90.2          83     9.8                         
  **Previous stay at camps/hostels**         No                         2880          92.1   247    7.9                  1.3 (1.0--1.6)
  Yes                                        1305                       89.9          147    10.1                        
  **Partner with STIs**                      No                         4021          91.3   381    8.7                  0.84 (0.47--1.5)
  Yes                                        164                        92.7          13     7.3                         
  **Partner infected with HCV**              No                         4050          91.6   371    8.4                  **1.8 (1.2--2.9)**
  Yes                                        135                        85.4          23     14.6                        
  **Unexplained fatigue in last 6 months**   No                         2889          93.3   207    6.7                  **2.0 (1.6--2.5)**
  Yes                                        1296                       87.4          187    12.6                        

® Reference category

In the studied population, there was an 8.6% prevalence of HCV antibodies with HCV viremia found in 83.8% of them (7.2%).

The EGCRISC has an average discriminating ability for persons\' HCV status as the area under curve (AUC) ranged from 0.65 for older males (above 45 years) to 0.84 for older females. Based on ROC curve analysis, the best cutoff point discriminating HCV positive and HCV negative cases for each gender in the two age strata are displayed in ([Fig 1](#pone.0168649.g001){ref-type="fig"}). As for males above 45, we respected the use of the best cutoff point of phase I model (8 *vs* 7) since it had higher reported sensitivity (70% *vs* 66%) and specificity (80% *vs* 58%).

![The scoring system for the selected risk factors.\
ROC curve analysis for the best cutoff point discriminating HCV positive and HCV negative status. Old cut off value was included in the table. Cutoff values respected in our prediction model are displayed in a red color font. \~ old cut off value](pone.0168649.g001){#pone.0168649.g001}

"[Table 4](#pone.0168649.t004){ref-type="table"}" cross tabulates the real HCV status and the risk status based on EGCRISC old and new cutoff points. The results of the old EGCRISC show a significant association and a considerable degree of agreement with the real HCV status in each category. The highest agreement levels were mainly for males and the lowest agreement level was for females \<45 years. This discrepancy in agreement levels was eliminated after the use of the new cutoff points of EGCRISC while keeping the significant association. The positive posttest probability ranged from 5% to 37.2% whereas the negative posttest probability was in the range 1% to 17%.

10.1371/journal.pone.0168649.t004

###### HCV status based on standard lab and extracted scoring system of selected risk factors.
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  Strata             Standard         Score Categories   *P*[\~](#t004fn001){ref-type="table-fn"}   (preTP) Agreement (%)   PPTP (%)   NPTP (%)   Score Categories   *P*[\~](#t004fn001){ref-type="table-fn"}   (preTP) Agreement (%)   PPTP (%)   NPTP (%)                                                 
  ------------------ ---------------- ------------------ ------------------------------------------ ----------------------- ---------- ---------- ------------------ ------------------------------------------ ----------------------- ---------- ---------- ------ ------ -------- -------- ------ ------ ------
  Male \<45 yrs      Anti-HCV ELISA   Negative           1123                                       69.9                    431        26.8       0.0001             72.3                                       8.3                     1.2        1554       96.7   0      0.0      \-       96.7           
  Positive           14               0.9                39                                         2.4                     53         3.3        0                  0.0                                                                                                                                    
  PCR                Negative         1126               70.1                                       443                     27.6       0.0001     71.8               5.7                                        1.0                     1126       70.1       443    27.6   0.001    71.8     5.7    1.0    
  Positive           11               0.7                27                                         1.7                     11         0.7        27                 1.7                                                                                                                                    
  Male \>45 yrs      Anti-HCV ELISA   Negative           576                                        61.1                    183        19.4       0.0001             68.1                                       26.5                    16.9       552        58.6   207    22.0     0.002    66.0   25.3   17.0
  Positive           117              12.4               66                                         7.0                     113        12.0       70                 7.4                                                                                                                                    
  PCR                Negative         593                63                                         192                     20.4       0.0001     69.1               23.0                                       14.4                    568        60.3       217    23.0   0.004    66.7     21.7   14.6   
  Positive           100              10.6               57                                         6.1                     97         10.3       60                 6.4                                                                                                                                    
  Females \<45 yrs   Anti-HCV ELISA   Negative           329                                        30.5                    720        66.7       0.028              33.2                                       3.9                     0.3        721        66.8   328    30.4     0.021    68.8   6.3    1.1
  Positive           1                0.1                29                                         2.7                     8          0.7        22                 2.0                                                                                                                                    
  PCR                Negative         329                30.5                                       729                     67.6       0.026      32.4               2.7                                        0.3                     724        67.1       334    31.0   0.034    68.6     4.6    0.69   
  Positive           1                0.1                20                                         1.9                     5          0.5        16                 1.5                                                                                                                                    
  Females \>45 yrs   Anti-HCV ELISA   Negative           287                                        30.2                    536        56.4       0.0001             42.7                                       18.2                    3.0        656        69.0   167    17.6     0.0001   79.4   37.2   4.2
  Positive           9                0.9                119                                        12.5                    29         3.0        99                 10.4                                                                                                                                   
  PCR                Negative         288                30.3                                       549                     57.7       0.0001     41.4               16.2                                       2.7                     660        69.4       177    18.6   0.0001   78.8     33.4   3.6    
  Positive           8                0.8                106                                        11.1                    25         2.6        89                 9.4                                                                                                                                    

\~Exact Sig. (2-sided) McNemar test

preTP = Pre test probability (Agreement)

PPTP = Positive posttest probability

NPTP = Negative posttest probability

For applicability we used the zones classification to rate the risk score instead of having a positive/negative test result. The limits for being at risk of having HCV based on validated scoring system of the selected risk factors are shown in ([S2 Table](#pone.0168649.s002){ref-type="supplementary-material"} and [Fig 2](#pone.0168649.g002){ref-type="fig"}). The risk is classified as low (subjects lie in the Green zone), borderline (subjects lie in Yellow zone), or high (subjects lie in Red zone).

![Limits for risk of having HCV based on the scoring system of the selected risk factors.\
The questions are not equally weighed.](pone.0168649.g002){#pone.0168649.g002}

"[Table 5](#pone.0168649.t005){ref-type="table"}" highlights the zones classification and performance in the four different groups. The negative predictive value (NPV) ranged from 82% for yellow and red zones in males \>45 years to 99% for younger groups. Positive predictive values (PPV) were high for red zones in older age groups compared to the younger age groups.

10.1371/journal.pone.0168649.t005

###### EGCRISC zones classification and performance.
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  Age Category Lab. Test   Zone             Yellow Zone   Red Zone                                                     
  ------------------------ ---------------- ------------- ---------- ------ ------ ------ ------ ------ ---- ---- ---- ----
  Male \<45 years          Anti-HCV ELISA   Negative      598        38.5   708    45.6   248    16.0   4    99   7    99
  Positive                 4                7.5           29         54.7   20     37.7                                
  PCR                      Negative         598           38.1       716    45.6   255    16.3   3      99   6    99   
  Positive                 4                10.5          21         55.3   13     34.2                                
  Male \>45 years          Anti-HCV ELISA   Negative      644        84.8   105    13.8   10     1.3    12   82   75   82
  Positive                 139              76.0          14         7.7    30     16.4                                
  PCR                      Negative         666           84.8       106    13.5   13     1.7    11     85   68   85   
  Positive                 117              74.5          13         8.3    27     17.2                                
  Female \<45 years        Anti-HCV ELISA   Negative      348        33.2   472    45.0   229    21.8   2    99   8    99
  Positive                 4                13.3          8          26.7   18     60.0                                
  PCR                      Negative         350           33.1       474    44.8   234    22.1   2      99   5    99   
  Positive                 2                9.5           6          28.6   13     61.9                                
  Female \>45 years        Anti-HCV ELISA   Negative      493        59.9   284    34.5   46     5.6    13   97   61   97
  Positive                 16               12.5          40         31.3   72     56.3                                
  PCR                      Negative         497           59.4       286    34.2   54     6.5    12     98   54   98   
  Positive                 12               10.5          38         33.3   64     56.1                                

Discussion {#sec010}
==========

Although active HCV infection has an estimated national prevalence of 4% in the population age 1--59 years\[[@pone.0168649.ref014]\], the present study revealed a seroprevalence of 8.6% and active infection in 7.2% of those aged \> 15 years. Egypt has a large reservoir of HCV and the disease transmission is ongoing \[[@pone.0168649.ref015], [@pone.0168649.ref016]\]. However, there is no adopted strategy for HCV case finding in primary health care settings in Egypt and the rates of detection remains beyond the CDC goals \[[@pone.0168649.ref017]\]. Spotting individuals at increased risk who should be screened for infection is a critical step. Our group has previously derived a simple risk assessment predication tool (EGCRISC) based on patient-reported yes/no questions to be used as a first-level screening tool in identifying subjects who should undergo serologic testing for HCV antibodies (phase I)\[[@pone.0168649.ref013]\]. In this study, we validated the proposed model in a sample depicting the Egyptian population.

Compared to the data derived from the first development phase and initial testing of EGCRISC, the probability threshold for HCV seropositivity based on our prediction model was increased except for the category male \>45 years, we respected the use of the old cutoff point which had better agreement and performance. These new cutoff points will oust the need for serologic HCV antibody testing in a considerable number of uninfected subjects. The testing counsel of the proposed tool agreed well with the HCV status in this study and this features its validity, high diagnostic value, and hopefully cost-effectiveness.

A number of worldwide studies ([Table 6](#pone.0168649.t006){ref-type="table"}) have developed or appraised questionnaire tools for HCV infection risk assessment \[[@pone.0168649.ref005], [@pone.0168649.ref018]--[@pone.0168649.ref022]\]. Of those that evaluated accuracy and feasibility in clinical practice, a harmony between sensitivity and specificity was respected to guarantee cogency, diagnostic performance, and cost-effectiveness of the selection method.

10.1371/journal.pone.0168649.t006

###### Literature overview of the different HCV risk assessment tools.
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  Reference                                                                           Study population                                                                                                                                                                Respondent (n)                                                                                                                                                                                                     Age (years)                              HCV prevalence                          Type of study                             Screening tool                                                                                                                                                                                     cut off discriminative point                                                            Sensitivity   Specificity
  ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------- --------------------------------------- ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------- -------------
  Lapane et al., 1998                                                                 Top of Formdatabase of a national hepatitis screening program that included self-referred individuals screened for viral hepatitis in 40 urban hospitals in USABottom of Form   13,997                                                                                                                                                                                                                                                      20%                                     cross sectional                           Risk Factors based Questionnaire (Model 1)                                                                                                                                                         Probability 7% in a mathematical model                                                  65.0%         84.0%
  29%                                                                                 Model 2                                                                                                                                                                         Individuals with any socially intrusive risk factors (history of IV drug use, history of sex with IV drug user) or socially nonintrusive risk factors (history of blood transfusion, male gender, age 30--49 yr)   69.0%                                    74.0%                                                                                                                                                                                                                                                                                                                                                                                      
  25%                                                                                 Model 3                                                                                                                                                                         Individuals with two or more socially nonintrusive risk factors.                                                                                                                                                   53.0%                                    77.0%                                                                                                                                                                                                                                                                                                                                                                                      
  12%                                                                                 Model 4                                                                                                                                                                         Performing ALT on all, followed by EIA on those with elevated ALT                                                                                                                                                  63.0%                                    92.0%                                                                                                                                                                                                                                                                                                                                                                                      
  Nguyen et al., 2005                                                                 patients attending general medicine practice and hepatology practice at Thomas Jefferson University hospital                                                                    207 with unknown HCV status and 222 HCV +ve patients                                                                                                                                                               18--60                                   1.5% in general medicine patients       cross sectional                           a 7 item questionnaire based on variables found significantly associated with HCV infection in multivariate model of exposures                                                                     4 or more risk factors are present                                                      24.4%         99.4%
  Mallette et al., 2008                                                               Veterans presenting for care and participated in risk stratification screening program at the Providence VA Medical Center (USA)                                                25,701                                                                                                                                                                                                             25--92 (mean = 58.7)                     7.30%                                   cross sectional                           a self-administered questionnaire identifying common HCV risk factors                                                                                                                              Patients who answer yes to any of risk factors are offered anti-HCV antibody testing.                 
  McGinn et al., 2008                                                                 patients attending an inner-city primary care clinic                                                                                                                            1000                                                                                                                                                                                                               55 (mean)                                8.30%                                   cross sectional                           A 27-item questionnaire assessing 5 HCV risk factor domains: work, medical, exposure, personal care, and social history. Questions were inspired from the literature and the clinical experience   1 or more positive domains                                                              90.0%         31.0%
  3 or more positive domains                                                          34.0%                                                                                                                                                                           97.0%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Zuure et al., 2010                                                                  patients with known HCV status                                                                                                                                                  289                                                                                                                                                                                                                36--59                                   0.1%-0.4% in general Dutch population   cross sectional                           core risk assessment questionnaire                                                                                                                                                                                                                                                         85.90%        64.30%
  extended risk assessment questionnaire                                                                                                                                                                                                                              89.40%                                                                                                                                                                                                             73.7%                                                                                                                                                                                                                                                                                                                                                                                                                               
  patients of an outpatient clinic for sexually transmitted infections (Netherland)   985                                                                                                                                                                             47--60                                                                                                                                                                                                             extended risk assessment questionnaire                                           90.0%                                     86.6%                                                                                                                                                                                                                                                                                                    
  Wand et al., 2012                                                                   IVDUs attended Needle and Syringe Programs in Australia                                                                                                                         16,127                                                                                                                                                                                                             34 (mean)                                51%                                     cross sectional and prospective cohorts   a brief self-administered questionnaire on demographic characteristics and injecting and sexual risk behaviors                                                                                     \>10                                                                                    89.0%         16.0%
  \>15                                                                                78.0%                                                                                                                                                                           33.0%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  \>20                                                                                60.0%                                                                                                                                                                           54.0%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  \>25                                                                                41.0%                                                                                                                                                                           70.0%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

The present study has several strengths, among which comes the internal validation of our predictive model through internal case control and cross sectional data sets. Categorizing risk factors by age and gender enhanced the properties of our scoring tool. Also, the large representative sample of 4579 participant is ideal in risk assessment. Furthermore, the use of a proportionally allocated population based sample asserts that the derived results feature the Egyptian population. The study conducted by McGinn et al., in USA was limited by surveying population coming from an inner-city primary care practice, thus the results do not represent the true community \[[@pone.0168649.ref021]\]. Other studies validated their tool on hospital based small samples \[[@pone.0168649.ref019], [@pone.0168649.ref022]\] or on certain risk groups \[[@pone.0168649.ref005], [@pone.0168649.ref020]\].

Internet screening appears appropriate, attainable, and more cost-effective comparing to other strategies as it abates health care consultation costs \[[@pone.0168649.ref022]\]. An interactive electronic version of EGCRISC is now available at [www.virus-c.com](http://www.virus-c.com/). The tool is enabled with a calculator for weighing the risk score and estimating the risk. Depending on the obtained score, the subject will be given a tailored recommendation that he/she should discuss with his/her professional healthcare provider. This instrument will empower the detection of silent chronic HCV cases in Egypt. People who are concerned about their probable HCV infection state will be boosted to assess their risk and pursue diagnosis. Filling out a risk assessment questionnaire via internet ensure anonymity and provide better chance for understanding its purpose. Individuals will therefore recall relevant information and disclose risky behaviors differently from those collected through interviewing in a survey or health care settings. However, this might result is difference in the sensitivity and specificity of our validated tool. Nevertheless, although most of individuals in Egypt can have access to internet, not all of them have sufficient literacy or mastery to employ it. According to the 2015 EHIS (Egypt Health Issues Survey)\[[@pone.0168649.ref014]\], 22% of women and 8% of men age 15--59 are illiterate. It also reported that around 37% of adult men and 22% of adult women use computer and internet at least once a week. These factors may represent a challenge for the wide use of our proposed web-based screening. Marketing the use of EGCRISC will be adequately advertised through mass media outlets. Egyptians are regularly exposed to mass media particularly the television (99%) that have been traditionally used to convey health messages to the population. Additionally, reports will be disseminated to health authorities recommending the wide use of EGCRISC in primary care settings. Training workshops for primary care providers are planned to be held after phase III (a governorate-based EGCRISC application phase).

Prediction questionnaire tool was proofed to be a adequate, feasible and conductive instrument, accomplishing the growing needs for the screening of several diseases including dementia \[[@pone.0168649.ref023]\], type 2 diabetes \[[@pone.0168649.ref024]\], osteoporosis \[[@pone.0168649.ref025]\], and HCV infection among high risk groups \[[@pone.0168649.ref005]\]. A composite screening tool was also developed for chronic kidney disease, cardiovascular disease and type 2 diabetes screening in the same individual \[[@pone.0168649.ref026]\]. Moreover, risk estimation approaches were envisaged as an alternative for the diagnosis of some diseases such as cancer and cardiovascular disorders and have been widely exploited in public health and clinical care decision-making process \[[@pone.0168649.ref006]\].

The perspectives of the current work are to assess the feasibility and potential shortcoming of risk-based screening using our proposed prediction tool in the clinical practice. Also, to address its cost effectiveness in HCV detection and the cost of treating early/minimal liver diseased populations. A future study is foreseen by our group to assess the cost-effectiveness of EGCRISC in internet-based and alternative programs compared with other strategies, such as mass screening or screening evidently high risk groups. The cost-effectiveness analysis should take into consideration not only abating eventual health care costs of identified HCV-infected individuals, but also expenditure associated with HCV patient who would not be detected using one of the aforementioned strategies. We also recommend further validation of our questionnaire tool particularly in countries and regions with comparable prevalence and setting to those in Egypt.

In conclusion, we have validated a simplified tool (EGCRISC) to assess HCV risk in the general population in Egypt and demonstrated its diagnostic value. EGCRISC can taper the need for mass serologic screening in those at apparently very low or no risk. Widespread use of electronic and self- or interviewer-administered risk-based screening strategy may facilitate and promote HCV screening and detection in diverse populations. Targeted HCV screening in high risk individuals is more cost-effective and can be beneficial in early identification of individuals at risk for progressive liver disease who may benefit from counseling and prompt treatment to reduce HCV-related liver injury. An impact analysis or randomized control trial of this model is warranted to evaluate both the clinical value and cost-effectiveness.
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